

Southern Africa Pharmaceuticals and Healthcare Report Q3 2012

<https://marketpublishers.com/r/SA6F3DBFCD2EN.html>

Date: June 2012

Pages: 150

Price: US\$ 1,295.00 (Single User License)

ID: SA6F3DBFCD2EN

Abstracts

Includes 3 FREE quarterly updates

The better-regulated markets of the Gulf Cooperation Council (GCC), South Africa and Israel remain the most rewarding and least risky for drugmakers operating in the Middle East and Africa (MEA). However, these markets are rapidly approaching maturity and are expected to grow only in the mid-to-high single digits. As pharmaceutical companies look to enter markets with higher potential, they will likely turn their attention first to the Gulf Levant and then North Africa, where population demographics, the regulatory framework and macroeconomic factors will facilitate growth.

Sub-Saharan African (SSA) countries remain the final frontier in terms of investment because the risks in these countries are higher and at present the rewards are lower. However, their appeal lies in the long term and the companies that establish their brands sooner rather than later will benefit most. Generally speaking, BMI has preferred the Southern African region over East Africa, which has recently been overtaken in attractiveness by West and Central Africa.

Change At The Top And Bottom In Q312, after two quarters away from the top spot, the UAE has returned to being the most attractive market in BMI's MEA Pharmaceutical Risk/Reward Ratings (RRR) matrix. The reason for the return is an increase the country's medium-term pharmaceutical market growth forecast, which has caused an increase in the UAE's industry rewards score. The higher forecast is primarily due to two factors: the lack of new price-containment measures on pharmaceuticals, which could have slowed market growth beyond 2012, and the increase in historic health expenditure data that undermine the case for the development of a two-tier healthcare market for poorer expatriates.

At the bottom of the table there has also been some movement, with Sudan slipping below Côte d'Ivoire in terms of attractiveness for drugmakers. The continued deterioration in Sudan's political environment, which looks to be heading towards conflict between the North and South, is likely to drive its score even lower in Q412. Furthermore, with Côte d'Ivoire returning to some semblance of stability and the removal of the vastly ineffectual universal free healthcare, its RRR score could improve in future.

Contents

Industry Business Environment Overview

Table: Pharmaceuticals & Healthcare Q312 Risk/Reward Ratings

Angola

SWOT Analysis

Angola Pharmaceuticals And Healthcare SWOT

BMI Industry View

Pharmaceutical Business Environment Ratings

Rewards

Risks

Market Summary

Regulatory Regime

Intellectual Property Issues

Pricing And Reimbursement

Regulatory Developments

Epidemiology

Clinical Trials Sector

Industry Forecast Scenario

Overall Market Forecast

Table: Pharmaceutical Sales, 2008-2016

Key Growth Factors – Industry

Table: Overall Healthcare Expenditure, 2008-2016

Table: Government Healthcare Expenditure, 2008-2016

Table: Private Healthcare Expenditure, 2008-2016

Key Growth Factors – Macroeconomic

Table: Angola Economic Activity, 2011-2016

Key Risks To BMI's Forecast Scenario

Competitive Landscape

Company Developments

Botswana

BMI Industry View

Pharmaceutical Business Environment Ratings

Rewards

Risks

Market Summary

Regulatory Regime

Intellectual Property Issues

Manufacturing Pharmaceuticals In Botswana

Research & Development

Pharmacovigilance

Industry Forecast Scenario

Overall Market Forecast

Table: Pharmaceutical Sales, 2008-2016

Key Growth Factors – Industry

Table: Overall Healthcare Expenditure, 2008-2016

Table: Government Healthcare Expenditure, 2008-2016

Table: Private Healthcare Expenditure, 2008-2016

Key Growth Factors – Macroeconomic

Table: Botswana Economic Activity, 2011-2016

Mozambique

SWOT Analysis

Mozambique Pharmaceuticals And Healthcare SWOT

BMI Industry View

Pharmaceutical Business Environment Ratings

Rewards

Risks

Market Summary

Regulatory Regime

Intellectual Property Issues

Pricing And Reimbursement

Regulatory Developments

Epidemiology

Clinical Trials Sector

Industry Forecast Scenario

Overall Market Forecast

Table: Pharmaceutical Sales, 2008-2016

Key Growth Factors – Industry

Table: Overall Healthcare Expenditure, 2008-2016

Table: Government Healthcare Expenditure, 2008-2016

Table: Private Healthcare Expenditure, 2008-2016

Key Growth Factors – Macroeconomic

Table: Mozambique Economic Activity, 2011-2012

Key Risks To BMI's Forecast Scenario

Competitive Landscape

Company Developments

Namibia

BMI Industry View

Pharmaceutical Business Environment Ratings

Rewards

Risks

Market Summary

Regulatory Regime

Zambia

BMI Industry View

Pharmaceutical Business Environment Ratings

Rewards

Risks

Market Summary

Zambia

Government Healthcare Reform

Regulatory Regime

Zambia

Pharmacovigilance (PV)

Industry Forecast Scenario

Namibia

Pharmaceutical Market Forecast

Table: Pharmaceutical Sales Indicators 2008-2016

Key Growth Factors – Macroeconomics

Namibia – Economic Activity

Healthcare Market Forecast

Table: Healthcare Expenditure Indicators 2008-2016

Table: Healthcare Governmental Indicators 2008-2016

Table: Healthcare Private Indicators 2008-2016

Industry Trends & Developments

Epidemiology

Zambia

Pharmaceutical Market Forecast

Table: Pharmaceutical Sales Indicators 2008-2016

Healthcare Market Forecast

Table: Healthcare Expenditure Indicators 2008-2016

Table: Healthcare Governmental Indicators 2008-2016

Table: Healthcare Private Indicators 2008-2016

Key Growth Factors – Macroeconomic

Zambia - Economic Activity

Company Profiles

Angola

Nova Angomedica

Botswana

Gemi Pharmacure

Mozambique

Sociedade Mocambicana de Medicamentos (SMM)

Table: Angola's Population By Age Group, 1990-2020 ('000)

Table: Angola's Population By Age Group, 1990-2020 (% of total)

Table: Angola's Key Population Ratios, 1990-2020

Table: Angola's Rural And Urban Population, 1990-2020

Demographic Outlook – Botswana

Table: Botswana's Population By Age Group, 1990-2020 ('000)

Table: Botswana's Population By Age Group, 1990-2020 (% of total)

Table: Botswana's Key Population Ratios, 1990-2020

Table: Botswana's Rural And Urban Population, 1990-2020

Demographic Outlook – Mozambique

Mozambique's Population By Age Group, 1990-2020 ('000)

Mozambique's Population By Age Group, 1990-2020 (% of total)

Mozambique's Key Population Ratios, 1990-2020

Mozambique's Rural And Urban Population, 1990-2020

Demographic Outlook - Namibia

Namibia's Population By Age Group, 1990-2020 ('000)

Namibia's Population By Age Group, 1990-2020 (% of total)

Namibia's Key Population Ratios, 1990-2020

Namibia's Rural And Urban Population, 1990-2020

Demographic Outlook - Zambia

Table: Zambia's Population By Age Group, 1990-2020 ('000)

Table: Zambia's Population By Age Group, 1990-2020 (% of total)

Table: Zambia's Key Population Ratios, 1990-2020

Table: Zambia's Rural And Urban Population, 1990-2020

Glossary

BMI Methodology

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Risk/Reward Ratings Methodology

Ratings Overview

Table: Pharmaceutical Risk/Reward Indicators

Weighting

Table: Weighting Of Components

Sources

I would like to order

Product name: Southern Africa Pharmaceuticals and Healthcare Report Q3 2012

Product link: <https://marketpublishers.com/r/SA6F3DBFCD2EN.html>

Price: US\$ 1,295.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SA6F3DBFCD2EN.html>